Sarah Ahn
YOU?
Author Swipe
View article: Data from Cancer Immunotherapy with T Cells Carrying Bispecific Receptors That Mimic Antibodies
Data from Cancer Immunotherapy with T Cells Carrying Bispecific Receptors That Mimic Antibodies Open
Tumors are inherently heterogeneous in antigen expression, and escape from immune surveillance due to antigen loss remains one of the limitations of targeted immunotherapy. Despite the clinical use of adoptive therapy with chimeric antigen…
View article: Data from Cancer Immunotherapy with T Cells Carrying Bispecific Receptors That Mimic Antibodies
Data from Cancer Immunotherapy with T Cells Carrying Bispecific Receptors That Mimic Antibodies Open
Tumors are inherently heterogeneous in antigen expression, and escape from immune surveillance due to antigen loss remains one of the limitations of targeted immunotherapy. Despite the clinical use of adoptive therapy with chimeric antigen…
View article: Supplementary Data from Cancer Immunotherapy with T Cells Carrying Bispecific Receptors That Mimic Antibodies
Supplementary Data from Cancer Immunotherapy with T Cells Carrying Bispecific Receptors That Mimic Antibodies Open
Supplementary figures 1-6
View article: Supplementary Data from Cancer Immunotherapy with T Cells Carrying Bispecific Receptors That Mimic Antibodies
Supplementary Data from Cancer Immunotherapy with T Cells Carrying Bispecific Receptors That Mimic Antibodies Open
Supplementary figures 1-6
View article: Figure S5 from CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells
Figure S5 from CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells Open
CD19-T cells show equivalent antitumor activity in a patient-derived xenograft (PDX) mantle cell lymphoma model in vivo.
View article: Figure S2 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Figure S2 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia Open
B7-H3 expression is retained on THP1 cells and patient-derived AML blasts after B7-H3.CAR-T treatment
View article: Figure S1 from CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells
Figure S1 from CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells Open
Modifications of the hinge and transmembrane domain
View article: Figure S5 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Figure S5 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia Open
B7-H3.CAR-Ts control leukemia growth in a patient-derived xenograft model of AML.
View article: Figure S4 from CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells
Figure S4 from CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells Open
Recurrent tumor cells in vivo
View article: Supplemental Methods from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Supplemental Methods from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia Open
Supplemental Methods
View article: Figure S3 from CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells
Figure S3 from CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells Open
CD19-T cells show equivalent antitumor activity in a lymphoma tumor model in vivo at a lower dose of CAR-T cells
View article: Supplementary Figures Legends from CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells
Supplementary Figures Legends from CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells Open
Supplementary Figures Legends
View article: Data from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Data from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia Open
Purpose:The development of safe and effective chimeric antigen receptor (CAR) T-cell therapy for acute myeloid leukemia (AML) has largely been limited by the concomitant expression of most AML-associated surface antigens on normal myeloid …
View article: Data from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Data from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia Open
Purpose:The development of safe and effective chimeric antigen receptor (CAR) T-cell therapy for acute myeloid leukemia (AML) has largely been limited by the concomitant expression of most AML-associated surface antigens on normal myeloid …
View article: Figure S4 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Figure S4 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia Open
B7-H3.CAR-Ts control leukemia growth in additional xenograft model using OCI-AML2 cells
View article: Figure S5 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Figure S5 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia Open
B7-H3.CAR-Ts control leukemia growth in a patient-derived xenograft model of AML.
View article: Figure S2 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Figure S2 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia Open
B7-H3 expression is retained on THP1 cells and patient-derived AML blasts after B7-H3.CAR-T treatment
View article: Data from CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells
Data from CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells Open
Purpose:CD19-redirected chimeric antigen receptor (CAR.CD19) T cells promote clinical responses in patients with relapsed/refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia (CLL). However, patients showing sustained c…
View article: Figure S1 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Figure S1 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia Open
Correlation of B7-H3 mRNA expression with AML features in existing datasets.
View article: Figure S5 from CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells
Figure S5 from CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells Open
CD19-T cells show equivalent antitumor activity in a patient-derived xenograft (PDX) mantle cell lymphoma model in vivo.
View article: Figure S1 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Figure S1 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia Open
Correlation of B7-H3 mRNA expression with AML features in existing datasets.
View article: Figure S3 from CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells
Figure S3 from CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells Open
CD19-T cells show equivalent antitumor activity in a lymphoma tumor model in vivo at a lower dose of CAR-T cells
View article: Figure S1 from CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells
Figure S1 from CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells Open
Modifications of the hinge and transmembrane domain
View article: Supplemental Methods from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Supplemental Methods from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia Open
Supplemental Methods
View article: Figure S4 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Figure S4 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia Open
B7-H3.CAR-Ts control leukemia growth in additional xenograft model using OCI-AML2 cells
View article: Table S1 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Table S1 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia Open
Clinical details associated with primary AML patient samples
View article: Figure S2 from CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells
Figure S2 from CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells Open
CAR targeting
View article: Supplementary Figures Legends from CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells
Supplementary Figures Legends from CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells Open
Supplementary Figures Legends
View article: Figure S3 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Figure S3 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia Open
Comparison of B7-H3 expression with B7-H3.CAR-T cytotoxicity.
View article: Data from CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells
Data from CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells Open
Purpose:CD19-redirected chimeric antigen receptor (CAR.CD19) T cells promote clinical responses in patients with relapsed/refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia (CLL). However, patients showing sustained c…